1
M
aterials
D
esign
A
nalysis
R
eporting (MDAR)
Checklist
for Authors
The
MDAR
framework establishes
a
minimum se
t of requirements in transparent reporting applicable to studies in the life sciences
(
see Statement of Task:
doi:10.31222/osf.io/9sm4x.
)
.
The MDAR checklist is a tool for authors, editors and others seeking to
adopt
the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the
MDAR Elaboration
Document
for
additional
context for the MDAR framework.
2
Materials
Antibodies
Yes (indicate where provided
:
page
no/section/legend
)
n/a
For commercial reagents,
provide
supplier
name, catalog
ue
number and RRID
,
if available.
Supplementary Material/Materials and Methods
Cell materials
Yes (indicate
where provided
:
page
no/section/legend
)
n/a
Cell lines:
P
rovide
species
information, strain.
Provide
accession number in repository
OR
supplier name, catalog number, clone number,
OR
RRID
n/a
Primary cultures:
P
rovide
species, strain, sex of
origin,
genetic modification status
.
n/a
Experimental animals
Yes (indicate where provided
:
page
no/section/legend
)
n/a
Laboratory animals:
P
rovide s
pecies, strain, sex, age,
genetic modification status
.
Provide
a
ccession
number in repository
OR
supplier name, catalog
number, clone number,
OR
RRID
Supplementary Materials/Materials and
Methods/Animal
Studie
s
Animal observed in or captured from the
field
:
Provide s
pecies, sex and age where
possible
n/a
Model organisms:
Provide
Accession number
in repository (where relevant)
OR
RRID
n/a
Plants and microbes
Yes (indicate where provided: page no/section/legend)
n/a
Plants:
provide species and strain, unique accession
number if available, and source (including locat
ion
for
collected wild specimens
)
n/a
Microbes:
provide species and strain
, unique
accession
number if available, and source
Supplementary Materials/Supplementary Table S
4
Human research participants
Yes (indicate where provided
:
page
no/section/legend
)
n/a
Identify authority granting ethics approval
(IRB
or
equivalent committee(s)
, provide reference number
for approval
.
n/a
Provide statement confirming informed consent
obtained from study participants.
n/a
Report on a
ge and sex
for all study
participants.
n/a
3
Design
Study
protocol
Yes (indicate where provided
:
page
no/section/legend
)
n/a
For clinical trials, provide the
trial registration
number
OR
cite
DOI
in manuscript.
n/a
Laboratory
protocol
Yes (indicate where provided
:
page
no/section/legend
)
n/a
Provide DOI or other citation details if
detailed step
-
by
-
step
protocols are available.
Supplementary Materials/Materials and Methods
Experimental study design (statistics details)
Yes (indicate where provided
:
page
no/section/legend
)
n/a
S
tate whether and
how the following have been
done
, or
if they were
not carried out
.
Sample size determination
n/a
a
Randomisation
Materials and Methods/Animal
Studies
Blinding
Materials and Methods/Animal
S
tudies
Inclusion/exclusion criteria
n/a
Sample definition and in
-
laboratory replication
Yes (indicate where provided
:
page
no/section/legend
)
n/a
State number of times the experiment was
replicated in laboratory
Figure legends
Define whether data
describe technical or biological
replicates
Figure legends
Ethics
Yes (indicate where provided
: pa
ge
no/section/legend
)
n/a
Studies involving human participants:
State details of
authority granting ethics approval (IRB
or equivalent
committee(s), provide reference number for
approval.
n/a
Studies involving experimental animals:
State details
of authority granting ethics approval (IRB
or
equivalent committee(s), provide reference number
for approval.
Supplementary
Materials/Materials and
Methods/Animal
Studie
s
Studies involving specimen and field samples: State if
relevant permits obtained, provide details of
authority approving study; if none were required,
explain why.
n/a
Dual Use Research of Concern
(DURC)
Yes (indicate where provided
:
page
no/section/legend
)
n/a
If
study is
subject to dual use research of
concern,
state
the authority granting approval and reference
number for the regulatory approval
n/a
4
Analysis
Attrition
Yes (indicate where
provided
:
page
no/section/legend
)
n/a
State if
sample or data point from the analysis
is
excluded,
and
whether the criteria for exclusion were
determined and specified in advance.
n/a
Statistics
Yes (indicate where provided
:
page
no/section/legend
)
n/a
Describe
statistical tests used and justify choice of
tests.
Supplementary Materials/Materials and
Methods/Statistical
A
nalysis and Figure legends
Data Availability
Yes (indicate where provided
:
page
no/section/legend
)
n/a
State
whether newly created da
tasets are available,
including protocols
for access or restriction on
access.
M
ain text/Data and materials availability
If data are publicly available,
provide
accessi
on
number in repository or DOI
or
URL.
M
ain text/Data and materials availability
If
publicly available data are reused,
provide
accession number in repository or DOI or URL, where
possible.
M
ain text/Data and materials availability
Code Availability
Yes (indicate where provided
:
page
no/section/legend
)
n/a
F
or all newly generated code and software essential
for replicating the main findings of the study:
State
whether the code or software is available.
n/a
If code is publicly available,
provide
accessi
on
number in
repository, or DOI or URL.
n/a
Reporting
Adherence to community standards
Yes (indicate where provided
: pag
e
no/section/legend
)
n
/a
MDAR framework
recommends adoption of
discipline
-
specific guidelines,
established and
endorsed through community initiatives. Journals
have their own policy about requiring specific
guidelines and recommendations to complement
MDAR.
n/a
State
if relevant guidelines
(eg., ICMJE, MIBBI,
ARRIVE)
have been followed, and whether a checklist
(eg., CONSORT, PRISMA, ARRIVE) is provided with
the
manuscript
.
n/a